In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.59 below Travere Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 370 other companies have achieved higher Quick Ratio than Travere Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1055 to 2030.

Explain Quick Ratio?
How much Cash & cash equivalents TVTX�s has?
What are TVTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TVTX/financial-strength

https://api.csimarket.com/api/v1/companies/TVTX/fundamentals

https://api.csimarket.com/api/v1/companies/TVTX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

TVTX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	56.15 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-51.46 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.59	Subscribe	Subscribe	Subscribe	Subscribe
TVTX's Total Ranking	# 2030	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	38.74 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	4.93 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 371
Healthcare Sector	# 671
Overall Market	# 2030

Quick Ratio Statistics
High	Average	Low
7.57	2.98	0.04
(Mar 31 2021)		(Jun 30 2013)

Financial Statements
Travere Therapeutics Inc 's Current Liabilities	$ 211 Millions	Visit TVTX's Balance sheet
Travere Therapeutics Inc 's Cash & cash equivalent	$ 124 Millions	Visit TVTX's Balance sheet
Source of TVTX's Sales		Visit TVTX's Sales by Geography

Cumulative Travere Therapeutics Inc 's Quick Ratio

TVTX's Quick Ratio for the trailling 12 Months

TVTX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-8.41 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-34.59 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.28	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3896	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	13.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-13.65 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to TVTX Financial Strength Comparisons >> Go to Compare TVTX Quick Ratio to its Competitors

News about Travere Therapeutics Inc Quick Ratio

Travere Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 15, 2024 - Travere Therapeutics, Inc. (NASDAQ: TVTX) has recently disclosed the granting of inducement equity grants to several new employees, a move aimed at attracting top talent to fuel the growth and innovation of the company. The Compensation Committee of Travere s Board of Directors authorized these grants on May 10, 2024, consisting of inducement stock options and inducement restricted stock units (RSUs) for a total of 51,500 shares of its common stock.
Specifically, the inducement grants included stock options that will allow the purchase of 25,000 shares of common stock, as well as RSUs covering 26,500 shares of Travere s common stock. Although these grants will be subject to the terms outlined in Traveres 2018 Equity Incentive Plan (2018 Plan), it should be noted that they were granted outside of the 2018 Plan. Instead, they were issued as inducements material to the successful recruitment of these new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $210.91 millions, cumulative Quick Ratio decreased to 1.28 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Travere Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2885 to 3896.

Explain Quick Ratio?
How much Cash & cash equivalents TVTX�s has?
What are TVTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 433
Healthcare Sector	# 886
Within the Market	# 3896

trailing twelve months Quick Ratio Statistics
High	Average	Low
6	3	0.15
(Mar 31 2021)		(Jun 30 2013)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Bridgebio Pharma Inc	1.57	$ 1,538.855 Millions	$ 977.237 Millions
Arcutis Biotherapeutics Inc	1.51	$ 259.460 Millions	$ 172.357 Millions
Regeneron Pharmaceuticals Inc	1.50	$ 9,301.100 Millions	$ 6,202.100 Millions
Emergent Biosolutions Inc	1.44	$ 175.700 Millions	$ 122.000 Millions
Arbutus Biopharma Corp	1.39	$ 337.490 Millions	$ 241.933 Millions
Compass Pathways Plc	1.36	$ 443.979 Millions	$ 325.863 Millions
Sarepta Therapeutics Inc	1.34	$ 878.776 Millions	$ 656.353 Millions
Zai Lab Limited	1.32	$ 559.658 Millions	$ 424.249 Millions
Urogen Pharma Ltd	1.31	$ 96.901 Millions	$ 74.031 Millions
Ani Pharmaceuticals Inc	1.28	$ 420.758 Millions	$ 328.717 Millions
Vertex Pharmaceuticals Inc	1.26	$ 6,303.300 Millions	$ 5,000.300 Millions
Nature s Sunshine Products inc	1.22	$ 89.377 Millions	$ 73.488 Millions
Ovid Therapeutics Inc	1.16	$ 13.811 Millions	$ 11.858 Millions
Filana Therapeutics Inc	1.12	$ 46.990 Millions	$ 41.946 Millions
Phathom Pharmaceuticals Inc	1.06	$ 184.558 Millions	$ 174.902 Millions
Eton Pharmaceuticals Inc	1.03	$ 55.628 Millions	$ 54.095 Millions
Akebia Therapeutics Inc	0.98	$ 159.254 Millions	$ 162.349 Millions
Acadia Pharmaceuticals Inc	0.97	$ 322.365 Millions	$ 332.217 Millions
Alkermes Plc	0.97	$ 631.314 Millions	$ 651.933 Millions
Geron Corporation	0.94	$ 69.794 Millions	$ 74.248 Millions
Mirum Pharmaceuticals Inc	0.86	$ 243.188 Millions	$ 283.080 Millions
Amphastar Pharmaceuticals Inc	0.86	$ 262.786 Millions	$ 306.303 Millions
Aclaris Therapeutics Inc	0.84	$ 20.394 Millions	$ 24.222 Millions
Seres Therapeutics Inc	0.84	$ 17.528 Millions	$ 20.893 Millions
Jazz Pharmaceuticals Plc	0.80	$ 2,036.400 Millions	$ 2,540.300 Millions
Zomedica Corp	0.80	$ 7.281 Millions	$ 9.096 Millions
Pfizer Inc	0.79	$ 25,140.000 Millions	$ 31,726.000 Millions
Xencor Inc	0.78	$ 59.622 Millions	$ 76.266 Millions
Janux Therapeutics Inc	0.77	$ 41.818 Millions	$ 54.247 Millions
Arcus Biosciences Inc	0.76	$ 151.000 Millions	$ 199.000 Millions

Date modified: 2026-11-03T16:39:47+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.